secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-08-03T20:47:12+00:00
Accession:  0001193125-26-330730
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma appoints James Ahlers as CFO effective July 30, 2026
------------------------------------------------------------------

- James Ahlers appointed CFO of Cue Biopharma effective July 30, 2026.
- Base salary $450,000; eligible for discretionary annual bonus target of 45% of base salary.
- Received inducement option for 51,000 shares at $30.40 and RSU for 25,500 shares, vesting quarterly over 4 years.
- Previously served as CFO of Intarcia Therapeutics, consulting CFO at Danforth Advisors, and roles at Intensity Therapeutics and RenovoRx.
- Severance: 9 months base plus prorated target bonus on qualifying termination; change-in-control triggers full equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/0001193125-26-330730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/d134183d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer